Analyzing the clinical-pathological characteristics of HER-2 Ultra-low breast cancer in a medium-sized Brazilian city: A brief communication

Authors

  • Tony Maronesi Bagio Faculdade de Medicina, Centro Universitário Católico Salesiano Auxilium (UNISALESIANO) https://orcid.org/0000-0002-9093-7125
  • Paulo Gil Katsuda Clínica Ginecológica Katsuda
  • Deolino João Camilo Júnior Instituto de Patologia de Araçatuba (IPAT)
  • José Cândido Caldeira Xavier Júnior Faculdade de Medicina, Centro Universitário Católico Salesiano Auxilium e Instituto de Patologia de Araçatuba (IPAT) https://orcid.org/0000-0003-0503-419X

DOI:

https://doi.org/10.34019/1982-8047.2023.v49.42185

Keywords:

Breast Neoplasms, Genes, erbB-2, Pathology

Abstract

N/A

Downloads

Download data is not yet available.

References

Instituto Nacional de Câncer (BR). Estimativa 2023: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2022 [acesso em 2023 jul 12]. Disponível em: https:// www.inca.gov.br/sites/ufu.sti.inca.local/files//media/ document//estimativa-2023.pdf

Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-49. DOI: 10.3322/caac.21660

Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. DOI: 10.1093/annonc/mdt303

Shi J, Zhang L, Geng C et al. Her-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study. Frontiers in Oncology. 2023; 13:1-9. DOI: 10.3389/fonc.2023.1210314

Giordano SH, Franzoi MAB, Temin S et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022; 40(23):2612-35. DOI: 10.1200/jco.22.00519

Venetis K, Crimini E, Sajjadi E et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci. 2022; 9:834651. DOI:10.3389/fmolb.2022.834651

Tuluhong D, Li X, Gao H et al. Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy. Eur J Cancer Prev. 2023; 32(4):377-87. DOI: 10.1097/CEJ.0000000000000813

Chen Z, Jia H, Zhang H, et al. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Research and Treatment. 2023; 202(2):313-23. DOI: 10.1007/s10549-023-07079-8

Allison K, Hammond M, Dowsett M et.al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020; 38(12):1346-66. DOI: 10.1200/jco.19.02309

Finkelman B, Zhang H, Hicks D et al. The evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations. Cancers. 2023; 15(3):808. DOI: 10.3390/cancers15030808

Lakhani SR, Ellis IO, Schnitt SJ et al. World Health Organization classification of tumours of the breast. 4th. ed. Lyon: IARC Press; 2012.

Downloads

Published

2024-01-29

How to Cite

1.
Maronesi Bagio T, Katsuda PG, Camilo Júnior DJ, Xavier Júnior JCC. Analyzing the clinical-pathological characteristics of HER-2 Ultra-low breast cancer in a medium-sized Brazilian city: A brief communication. HU Rev [Internet]. 2024Jan.29 [cited 2024Nov.23];49:1-3. Available from: https://periodicos.ufjf.br/index.php/hurevista/article/view/42185

Issue

Vol. 49 (2023)

Section

Short communications

License

Copyright (c) 2024 Tony Maronesi Bagio, Paulo Gil Katsuda, Deolino João Camilo Júnior, José Cândido Caldeira Xavier Júnior

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Cessão de Primeira Publicação à HU Revista

Os autores mantém todos os direitos autorais sobre a publicação, sem restrições, e concedem à HU Revista o direito de primeira publicação, com o trabalho licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento irrestrito do trabalho, com reconhecimento da autoria e crédito pela citação de publicação inicial nesta revista, referenciando inclusive seu DOI.